Covidien Declares Quarterly Cash Dividend

DUBLIN, Ireland--(BUSINESS WIRE)-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per ordinary share. The dividend is payable on August 19, 2011, to shareholders of record on August 1, 2011.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.



CONTACT:

Covidien
Eric Kraus, 508-261-8305
Senior Vice President
Corporate Communications
[email protected]
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
[email protected]
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
[email protected]
or
Todd Carpenter, 508-452-4363
Director
Investor Relations
[email protected]

KEYWORDS:   United States  Europe  North America  New York  Ireland

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

The top dose of Regeneron's COVID-19 antibody lowered virus levels and relieved symptoms more quickly than placebo in non-hospitalized patients.

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.